Quote:
Originally Posted by sweeps
Teva is an obvious choice.
|
Yes indeed! I've look at that along with Barr, Watson, Perrigo, Mylan... and of course, all the major names are also announcing their own competing generics as well....
You know, maybe it's a space that's just way over my head right now. Shotgun approach comes to mind, but not practical to DIY.... A specialized ETF somewhere would be better.
But maybe it's best if I leave that alone for now. That or just stay with pharma retailers....
Anyway, just thinking out loud, but still open to suggestions.